Acid Alpha-Glucosidase (GAA)
Glycogen storage disease (GSD) is a rare genetic disease that results from a defect in an enzyme required for glycogen synthesis or degradation resulting in the formation of glycogen with abnormal structure, or the excessive accumulation of glycogen in different tissues. At least 10 distinct types of the inherited disorder of glycogen storage have been known. GSD type II is an autosomal recessive disorder caused by a deficiency of acid α-glucosidase (encoded by GAA gene). The enzyme degrades α-1,4 and α-1,6 glycosidic linkage in glycogen, maltose, and isomaltose. The deficiency of GAA results in excessive accumulation of glycogen within lysosomes and in cytoplasm ultimately leading to tissue damage. It predominately affects the heart and skeletal muscles resulting in muscular weakness and cardiomegaly.
The infantile form, also known as Pompe disease, is a life-threatening condition presenting in the first few months of life. It is characterized by muscle hypotonia, weakness, cardiomyopathy and eventually death due to cardiorespiratory failure. Juvenile or adult-onset forms are milder and may appear in the second or third decade of life with difficulty in walking. Enzyme replacement therapy with recombinant human acid α-glucosidase can greatly improve the clinical outcome of Pompe disease. Early diagnosis of Pompe disease is very crucial since the early treatment of infants with Pompe disease can significantly reduce the morbidity and mortality associated with this disease. Measurement of acid α-glucosidase activity in a skeletal muscle biopsy, peripheral blood cells, urine or cultured skin fibroblasts can be a diagnostic test for GSD type II.
- Diagnosis of glycogen storage disease type II (Pompe disease)
- Therapy and disease management
Decreased in:
- Pompe disease (glycogen storage disease type II)
> 0.5 nmol/mL/h
Whole blood, dried blood spots (DBS).
Stability
- Ambient: 87 days (preferable)
- Refrigerated: 87 days
- Frozen: 87 days
- Can J Neurol Sci. 2016;43:472-85. [PMID: 27055517]
- JAMA Neurol. 2013;70:923-7. [PMID: 23649721]
- Pediatr Neonatol. 2013;54:219-27. [PMID: 23632029]
- Mol Genet Metab. 2008;93:275-81. [PMID: 18078773]
- Neurology. 2008;71:S4-11. [PMID: 19047572]
- Curr Mol Med. 2002;2:145-66. [PMID: 11949932]
- Clin Chem. 2001;47:1378-83. [PMID: 11468225]